-
公开(公告)号：KR1020020073918A
公开(公告)日：2002-09-28
申请号：KR1020010013859
申请日：2001-03-17
Applicant: 신풍제약주식회사
IPC: C07D501/12
Abstract: PURPOSE: Provided is a process for preparing amorphous form of cefuroxime axetil, thereby producing amorphous form of cefuroxime axetil, which is excellent in elution in a living body and has stability, in high yield and purity. CONSTITUTION: The amorphous cefuroxime axetil represented by the formula(1) is manufactured by the steps of: dissolving cefuroxime axetil in a polar organic solvent; passing CO2 gas therethrough; and adding a water soluble solution containing inorganic salts to precipitate amorphous cefuroxime axetil.
Abstract translation: 目的：提供头孢呋辛酯无定形形式的方法，由此生产无机形式的头孢呋辛酯，其在生物体中的洗脱性优异且稳定性高，产率高，纯度高。 构成：由式（1）表示的无定形头孢呋辛酯通过以下步骤制造：将头孢呋辛酯在极性有机溶剂中溶解; 使二氧化碳气体通过; 并加入含有无机盐的水溶性溶液以沉淀无定形头孢呋辛酯。
-
公开(公告)号：KR1020020046407A
公开(公告)日：2002-06-21
申请号：KR1020000076298
申请日：2000-12-14
Applicant: 신풍제약주식회사
IPC: A61K9/08
CPC classification number: A61K9/0019 , A61K31/192 , A61K47/02
Abstract: PURPOSE: Provided is a pharmaceutical composition for intramuscular injection containing loxoprofen having excellent anti-inflammatory effects, as an active ingredient, and its pharmaceutically acceptable salts. CONSTITUTION: The pharmaceutical composition for intramuscular injection contains loxoprofen represented by the formula(1) or its pharmaceutically acceptable salts. It is manufactured by dissolving loxoprofen or its pharmaceutically acceptable salt, a stabilizing agent or solution adjuvant in water for injection then sterilizing it.
Abstract translation: 目的：提供含有作为活性成分的优良抗炎作用的洛索丙芬及其药学上可接受的盐的肌内注射用药物组合物。 构成：用于肌内注射的药物组合物含有由式（1）表示的洛索洛芬或其药学上可接受的盐。 它是通过将洛索洛芬或其药学上可接受的盐，稳定剂或溶液佐剂溶解在水中，然后对其进行消毒而制造的。
-
13.发明公开혈소판 응집 저해 효과를 갖는 화합물 및 그 염, 그리고 이를 포함하는 혈전성 질환 예방 또는 치료용 조성물 审中-实审具有抑制血小板聚集及其盐的抑制作用的化合物及其组合物，用于预防或治疗血栓形成疾病
公开(公告)号：KR1020170028858A
公开(公告)日：2017-03-14
申请号：KR1020160113284
申请日：2016-09-02
Applicant: 신풍제약주식회사
IPC: C07D495/04 , C07D261/20 , C07D413/04 , A61K31/4365 , A61K31/423 , A61K31/5375
CPC classification number: A61K31/423 , A61K31/4365 , A61K31/5375 , C07D261/20 , C07D413/04 , C07D495/04
Abstract: 본발명은혈소판응집저해효과를갖는신규한화합물및 그염류에관한것으로서, 더욱상세하게는전단응력에의한혈소판응집(shear stress-induced platelet aggregation)을선택적으로저해하는새로운혈소판응집저해제및 이를유효성분으로하는약학적조성물및 그제조방법에관한것이다.
Abstract translation: 本发明涉及具有抑制血小板聚集作用的新型化合物及其盐，更具体地，涉及：特异性抑制剪切应激诱导的血小板聚集的新型血小板聚集抑制剂; 含有该活性成分的药物组合物; 及其制备方法。
-
公开(公告)号：KR101710441B1
公开(公告)日：2017-02-28
申请号：KR1020150187679
申请日：2015-12-28
Applicant: 신풍제약주식회사
Abstract: 본발명은활성성분으로서칸데사르탄또는칸데사르탄실렉세틸및 암로디핀또는이의약학적으로허용가능한염을함유하는정제에있어서, 상기활성성분의안정성및 용출성을유의적으로향상시키기위하여특정가용화제를사용한정제에관한것이다. 또한, 본발명은상기정제를제조하는방법에관한것이다.
Abstract translation: 本发明是一个特定的增溶剂，以改善活性成分的稳定性和溶出特性显著在含有坎地沙坦或坎地沙坦tansil齿条十六烷基和氨氯地平或其药用盐的片剂uiyakhak以往作为活性成分的 Lt。 本发明还涉及制备所述片剂的方法。
-
公开(公告)号：KR100699457B1
公开(公告)日：2007-03-27
申请号：KR1020050066421
申请日：2005-07-21
Applicant: 신풍제약주식회사
IPC: C07D337/14
Abstract: 본 발명은 약학적 활성을 가지는 하기의 구조식 I의 화합물 2-(10,11-디히드로-10-옥소벤조[
b,f ]티에핀-2-일)프로피온산(이하, '구조식 I의 디벤조티에핀 유도체'라 칭한다) 및 그 중간체인 하기의 구조식 IV의 고리화된 할로케톤 화합물의 제조방법에 관한 것이다:
상기 식에서 X는 할로겐원자이다.
본 발명의 제조방법에 따르면 종래 방법에 비해 간단한 방법으로 약학적 활성을 가지는 구조식 I의 디벤조티에핀 유도체를 고순도 및 고수율로 제조할 수 있다.
디벤조티에핀 유도체, 소염진통작용, 고리화반응, 제조 수율-
Patent Agency Ranking
公开(公告)号：KR1020070011824A
公开(公告)日：2007-01-25
申请号：KR1020050066421
申请日：2005-07-21
Applicant: 신풍제약주식회사
IPC: C07D337/14
Abstract: A method for preparing a dibenzothiepin derivative is provided to obtain the pharmaceutically active dibenzothiepin derivative with high purity and high yield through a simple process. The method for preparing a dibenzothiepin derivative represented by the formula(I) comprises the steps of: (a) reacting a propiophenone represented by the formula(II) with a halogenating agent to obtain a halo-ketone compound represented by the formula(III); (b) reacting the compound(III) with a condensing agent to obtain a cyclized halo-ketone compound represented by the formula(IV); (c) reacting the compound(IV) with an alkylorthoformate to obtain a cyclized haloacetal represented by the formula(V); (d) reacting the compound(V) with a zinc halide to obtain an ester compound represented by the formula(VI); and (e) hydrolyzing the compound(VI) to prepare the compound(I). In the formulae, X is halogen, and R1 is C1-6 alkyl, phenyl or phenyl having a substituent selected from the group consisting of H, halogen, C1-6 alkyl, and hydroxy.
Abstract translation: 提供了制备二苯并硫代衍生物的方法，以通过简单的方法获得高纯度和高产率的药物活性二苯并硫代衍生物。 制备由式（I）表示的二苯并硫代衍生物的方法包括以下步骤：（a）使由式（II）表示的苯丙酮酮与卤化剂反应，得到由式（III）表示的卤代酮化合物， ; （b）使化合物（III）与缩合剂反应，得到式（IV）所示的环化的卤代酮化合物; （c）使化合物（Ⅳ）与原甲酸烷基酯反应得到由式（Ⅴ）表示的环化的卤代缩醛; （d）使化合物（V）与卤化锌反应，得到式（VI）表示的酯化合物; 和（e）水解化合物（VI）以制备化合物（I）。 在该式中，X是卤素，R 1是C 1-6烷基，苯基或具有选自H，卤素，C 1-6烷基和羟基的取代基的苯基。
-
公开(公告)号：KR1020060039286A
公开(公告)日：2006-05-08
申请号：KR1020040088413
申请日：2004-11-02
Applicant: 신풍제약주식회사
IPC: A61K31/357
CPC classification number: A61K31/357 , A61K31/4375 , Y02A50/411 , A61K2300/00
Abstract: The present invention relates to an orally administrable antimalarial combined preparation containing artemisinine or its derivatives, and pyronaridine or its salts, as active ingredients, with pharmaceutically acceptable carriers, and to preparation process thereof.
-
公开(公告)号：KR100405161B1
公开(公告)日：2003-11-12
申请号：KR1020000076298
申请日：2000-12-14
Applicant: 신풍제약주식회사
IPC: A61K9/08
CPC classification number: A61K9/0019 , A61K31/192 , A61K47/02
Abstract: Disclosed is a formulation for intramuscular injection containingloxoprofen or a pharmaceutically acceptable salt thereof, having an excellent anti-inflammatory analgesic effect, as an active ingredient.
Abstract translation: 本发明公开了含有洛索洛芬或其药学上可接受的盐作为有效成分，具有优异的消炎镇痛作用的肌内注射用制剂。
-
公开(公告)号：KR1020010077337A
公开(公告)日：2001-08-17
申请号：KR1020000005071
申请日：2000-02-02
Applicant: 신풍제약주식회사
IPC: C07C229/00
Abstract: PURPOSE: An intermediate for preparing £2-(2,6-dichloroanilino)phenyl| acetoxyacetic acid (referred as "aceclofenac") used as an anti-inflammatory and analgesic agent, and methods for preparing aceclofenac are provided to improve production yield and purity without a process of waste heavy metal. CONSTITUTION: The intermediate which is used for preparing aceclofenac represented by the formula 1, is represented by the formula 2, wherein R1 and R2 are independent of each other and are an alkyl group of C1-C4. Aceclofenac is prepared by selectively hydrolyzing the intermediate of the formula 2 by using an acid in organic solvent. Preferably, the acid is HCl, H2SO4 or methanesulfonic acid; the solvent is alkyl acetate of C1-C5; and the reaction temperature is 20-40 deg.C. The intermediate of the formula 2 is prepared by reacting the alkali metal salt of compound of the formula 3 with the compound of the formula 4(X-CH2-COO-CH2OR¬1OR¬2) in solvent, wherein R1 and R2 are independent each other and are an alkyl group of C1-C4, and X is a halogen atom. Preferably X is Cl or Br; and the solvent is DMF or DMSO.
Abstract translation: 目的：制备2-（2,6-二氯苯胺基）苯基的中间体 用作抗炎和止痛剂的乙酰氧基乙酸（称为“醋氯芬酸”），以及制备醋氯芬酸的方法，以提高生产产率和纯度，而无需重金属废物。 构成：用于制备由式1表示的醋氯芬酸的中间体由式2表示，其中R 1和R 2彼此独立并且是C 1 -C 4的烷基。 通过在有机溶剂中使用酸选择性水解式2的中间体来制备醋氯芬酸。 优选地，酸是HCl，H 2 SO 4或甲磺酸; 溶剂是C1-C5的烷基乙酸酯; 反应温度为20-40℃。 式2的中间体通过使式3的化合物的碱金属盐与式4的化合物（X-CH 2 -COO-CH 2 OR 1 OR 2）在溶剂中反应制备，其中R 1和R 2各自独立地 另外是C1-C4的烷基，X是卤素原子。 优选地，X是Cl或Br; 溶剂为DMF或DMSO。
-
公开(公告)号：KR100623322B1
公开(公告)日：2006-09-19
申请号：KR1020040088413
申请日：2004-11-02
Applicant: 신풍제약주식회사
IPC: A61K31/357
CPC classification number: A61K31/357 , A61K31/4375 , Y02A50/411 , A61K2300/00
Abstract: 본 발명은 약제학적으로 허용되는 담체와 함께, 유효성분으로서 알테미시닌(artemisinine) 또는 그의 유도체 및 피로나리딘(pyronaridine) 또는 그의 염을 포함하는, 경구투여용 항말라리아 제제에 관한 것이다.
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.026 seconds)
